Home - CAR-T cell therapy
The Post Graduate Institute of Oncological Sciences and Research of the Malabar Cancer Centre (MCC) in Kerala’s Thalassery completed CAR-T cell therapy, a cutting-edge cancer treatment. A 19-year-old patient with acute lymphoblastic leukaemia underwent this treatment at the MCC. The CAR-T cells were produced by ImmunoACT, the only approved CAR-T cell company in India. The treatment, which normally costs around ₹50 lakh, was made available for ₹30 lakh through the “Patient Assistance Programme”. Various government schemes also supported the treatment.
What is CAR-T cell therapy?
CAR-T cell therapy is an immunotherapy that uses genetically modified T cells to fight cancer. T cells are a type of white blood cell that plays a crucial role in the immune system. In CAR-T cell therapy, T cells are collected from the patient, genetically modified in a laboratory, and reinfused into the patient to target cancer cells. This therapy is known for its ability to genetically re-program the immune system of patients to combat cancer. It is designed to treat various diseases, including acute lymphocytic leukaemia, multiple myeloma, glioblastoma, and hepatocellular carcinoma.
Benefits of CAR-T cell therapy
- Targets cancer cells specifically, sparing healthy cells
- Effective for treating resistant blood cancers
- It can be a one-time treatment
- Fewer side effects compared to traditional cancer treatments
- Improves quality of life for patients
- Only a shorter hospital stay is required
- CAR-T cell therapy is a rapidly evolving field, with ongoing research.
State Health Minister Veena George congratulated the team, including the director of MCC for the achievement.
Accrediation
Address
MALABAR CANCER CENTRE (POST GRADUATE INSTITUTE OF ONCOLOGY SCIENCES & RESEARCH), Moozhikkara (P.O), Thalassery, Kannur District, Kerala, India-670103
QR Code
